EMA panel signs off on AstraZeneca Imfinzi's use in biliary tract cancer
Lisa Maree Williams         

A committeeÂ of the European Medicines Agency (EMA)Â recommended the expanded approval of AstraZeneca's (NASDAQ:AZN) Imfinzi (durvalumab) to include first-line treatment of biliary tract cancer.
The EMA's Committee for Medicinal Products for Human Use (CHMP)Â adopted a new indication forÂ Imfinzi, in combination with chemotherapies gemcitabine and cisplatin, as a firstâline treatment for adults with unresectable or metastatic biliary tract cancer.
Imfinzi is already approved to treat certain types of lung cancer.
The European Commission, which generally follows the opinion of the CHMP, will now decide on the change to the terms of the marketing authorization of Imfinzi.